⌘K
t
Scancell Holdings plc allotted and issued 620,000 new ordinary shares of £0.001 each on July 1, 2024, under its block listing facility. Following this issue, the total number of ordinary shares in issue is 929,599,977. Additionally, the company announced its Nominated Adviser and Joint Broker changed its name to Panmure Liberum Limited.
| Date | 1 Jul 2024 |
| Time | 07:00:06 |
| Category | Miscellaneous |
| ID | 4774U |
1 July 2024
Scancell Holdings plc
("Scancell" or the "Company")
Block Listing Return and Total Voting Rights
Change of Name of Nominated Adviser and Joint Broker
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that it has allotted and issued a further 620,000 new ordinary shares of £0.001 each ("Ordinary Shares"), pursuant to its block listing facility, in satisfaction of the exercise of share options granted under the Company's existing options plan.
Following this issue, there will be a total of 929,599,977 Ordinary Shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
Block Listing Return
The Company makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
|
Name of applicant: |
Scancell Holdings plc |
||||
|
Number and class of securities originally admitted: |
2,880,000 ordinary shares of £0.001 each |
||||
|
Date of admission: |
17 April 2023 |
||||
|
Period of return: |
From: |
17 October 2023 |
To: |
30 June 2024 |
|
|
Balance of unallotted securities under scheme(s) from previous return: |
620,000 |
||||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
0
|
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
620,000
|
||||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
0 |
||||
|
Total number of securities in issue at the end of the period |
929,599,977 |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change of Name of Nominated Adviser and Joint Broker
The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.
|
For further information, please contact: |
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Panmure Liberum Limited (Nominated Advisor and Joint Broker) Emma Earl, Freddy Crosslet, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)
|
+44 (0) 20 7886 2500 |
|
WG Partners LLP (Joint Broker) |
+44 (0) 20 3705 9330 |
|
David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby
|
|
|
ICR Consilium |
+44 (0) 20 3709 5700 |
|
Mary-Jane Elliott/Angela Gray/Lindsey Neville |
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/